Brain and Blood Vessel Health Following Endometriosis Treatment in People With Endometriosis

Sponsor
Colorado State University
Study ID
NCT07799246
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Endometriosis
  • Endometriosis (Diagnosis)
  • Endometriosis and Dysmenorrhea

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Investigate how norethindrone acetate, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health — DRUG
    Eligible participants will prospectively be randomized to one of three medications approved for the treatment of endometriosis symptoms.
  • Investigate how Orlissa, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health — DRUG
    Eligible participants will prospectively be randomized to one of three medications approved for the treatment of endometriosis symptoms.
  • Investigate how Oriahnn, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health — DRUG
    Eligible participants will prospectively be randomized to one of three medications approved for the treatment of endometriosis symptoms.

Study Details

This research study wants to understand how medications used to treatment symptoms of endometriosis impact brain health in patients with endometriosis.

Key Dates

First listed
Sep 2, 2026
Start date
Oct 1, 2026
Status verified
Aug 2026
Primary completion
Apr 30, 2029
Completion
Jun 30, 2029

Study Design

Enrollment
45 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Norethindrone acetate
    5 mg norethindrone acetate pill, taken daily for \~28 days, approved to treat symptoms of endometriosis.
  • Active Comparator: Orlissa
    Oral gonadotropin releasing antagonist, taken daily for \~28 days, approved for the treatment of moderate-to-severe endometriosis symptoms
  • Active Comparator: Oriahnn
    Oral gonadotropin releasing antagonist, taken daily for \~28 days, with estrogen and progestin add-back.

Primary Outcome Measure

Cerebral blood flow [ Time Frame: Baseline and ~28 days ]

Central Contacts

Find similar trials

Nationwide
Endometriosis trialsWomen's health trialsFertility trials

Related Studies